

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Motoharu SEIKI et al.

Confirmation No. : 5607

Group Art Unit: 1642

Appln. No. : 10/551,780

(National Stage of PCT/JP2004/004876)

Examiner: Mark HALVORSON

I.A. Filed : April 2, 2004

For : LIPID MEMBRANE STRUCTURE CONTAINING ANTI-MT-MMP
MONOCLONAL ANTIBODY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98 and further to the Information Disclosure Statement filed May 4, 2007, Applicants hereby direct the Examiner's attention to the a Supplementary European Search Report issued in the counterpart European application on August 27, 2010, a copy of which is submitted herewith. The following documents are cited in the Supplemental European Search Report.

WO 98/22092 A1

EP 1 170 018 A1

WO 93/25255 A1

Lundberg et al., "Conjugation of an Anti-B-Cell Lymphoma Monoclonal Antibody. LL2, to Long-Circulating Drug-Carrier Lipid Emulsions", Journal of Pharmacy and Pharmacology, Royal Pharmaceutical Society of Great Britain, Vol. 51, No. 10, January 1, 1999, pages 1099-1105.

Maruyama, "PED-Immunoliposome", Bioscience Reports, Springer, New York, US, Vol. 22, No. 2, April 1, 2002, pages 251-266.

Applicants note that US 2005/0074499 A1 is a family member of EP 1 170 018 A1.

Copies of the above-noted documents (with the exception of the U.S. patents publication) are enclosed together with a duly completed Form PTO-1449. The Examiner is therefore requested to consider each of these documents, and to make them of record in this application by appropriately signing the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the signed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.


In accordance with 37 C.F.R. 1.97(e), the undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement. Of course, this statement does not apply to information that has previously been cited by Applicant or the Examiner in the present application as that information is already of record and no certification is necessary.

Moreover, Applicants note that the U.S. family member is not cited in the Supplementary European Search Report and is being submitted as a family member of a cited document.

Applicants hereby authorize the charging of any required fee necessary for consideration of the documents cited herein to Deposit Account No. 19-0089.

If there should be any questions, the Examiner is respectfully invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Motoharu SEIKI et al.



Bruce H. Bernstein
Reg. No. 29,027

October 13, 2010
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Arnold Turk
Reg. No. 33094